IL17A and psoriasis: In the study, skin lesions from 40 psoriasis patients who were participating in a randomized, double-blind, and placebo-controlled trial of ixekizumab, an IL-17 inhibitor, in which they received 5 mg, 15 mg, 50 mg, and 150 mg ixekizumab or placebo at baseline and at weeks 2 and 4 were studied [22].